Identify novel compounds for treatment of patients with acute kidney injury (AKI) to prevent development of chronic kidney disease (CKD).
Worldwide, in 2017, the total number of individuals with chronic kidney disease (CKD), acute kidney injury (AKI), and those receiving renal replacement therapy (RRT) exceeded 850 million. Mortality from CKD is increasing faster than mortality for most other causes and is expected to become the fifth global cause of death by 2040. Patients with AKI have a 9-fold increased risk of developing CKD. There is a clear medical need to develop novel treatment options to prevent AKI and/or to treat AKI to prevent AKI-to CKD transition.
Funding agency: European Union – MSCA training network
Status: Ongoing
Timeline: 2024 – 2028